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Purpose: Recent studies suggest new mechanisms of Botulinum toxin (BoNT) 
other than inhibiting acetylcholine (ACh) release from nerve terminals. The aim of 
this study was to determine whether other mechanisms for BoNT exist, so that it 
directly inhibits smooth muscle contraction. Materials and Methods: Guinea pig 
antral muscle strips were studied in vitro after 2 hours of exposure to Botulinum 
toxin type A (BoNT/A). Contractile responses to electric field stimulation (EFS), 
high K+ (60 mM) and ACh (100 μM) were evaluated 24 and 48 hours after antral 
intramuscular injection of BoNT/A or vehicle. Results: BoNT/A inhibited muscu-
lar contraction caused by high K+ and ACh. Contractile responses to low (1 & 4 
Hz) and high (8 & 20 Hz) frequency EFS of antral muscle strips 24 and 48 hours 
after antral intramuscular injection of BoNT/A were significantly inhibited. Con-
clusion: The ability of BoNT/A to directly inhibit antral muscular contractility 
suggests a new mechanism for the pharmacologic actions of BoNT-direct inhibi-
tion of muscular contraction.
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INTRODUCTION
Botulinum toxin (BoNT) is the most powerful inhibitor of muscular contraction. It 
is produced by the bacterium Clostridium botulinum, and seven serologically dif-
ferent subtypes (A though G) exist in nature.1 One subtype is Botulinum toxin type 
A (BoNT/A), which has potent neuromuscular blocking action with fewer limita-
tions2 and is used as a therapeutic agent to treat spastic disorders including strabis-
mus, hemifacial spasm, achalasia and skin wrinkles.3
BoNT/A consists of a heavy chain of 100 kDa and a light chain of 50 kDa. The 
heavy chain mediates its cellular adherence and cytoplasmic entry of the light chain,4 
whereas the light chain catalyzes the cleavage of a 25 kDa synaptosomal associat-
ed protein (SNAP-25; a protein that mediates synaptic vesicle membrane docking 
and fusion) at the neuromuscular junction, thereby preventing neurotransmitter re-
lease and inducing paralysis.1 Typically, BoNT/A causes reversible denervation at-
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Use Committee.
Antral intramuscular injection of BoNT/A & muscle 
strip preparation
Guinea pigs were anesthetized with intraperitoneal injec-
tions of pentobarbital (35-40 mg/kg). A short abdominal in-
cision was made, and the antrum of the stomach was isolat-
ed. Guinea pigs were injected with BoNT/A using a 27G 
needle. A total of 4 & 10 U of BoNT/A were diluted in 1 
mL of saline and injected subserosally into the four cardinal 
points of the antrum: on the small and large curve, and on 
the posterior and anterior wall (1 & 2.5 U in each 0.25 mL 
injection, BoNT/A group). The control animals were anes-
thetized and laparotomized, but injected with saline. At 24 
and 48 hours after injection of BoNT/A, antral muscle strips 
from control guinea pigs were prepared by exactly the same 
way as described previously.
Experimental protocols
Muscle strips were studied in vitro for their contractile re-
sponses to electrical field stimulation (EFS), high K+ (60 
mM) and ACh (100 μM). First, BoNT/A was added in con-
centrations of 2, 4, or 10 U. EFS (4 Hz, 60 s) was done every 
30 min for 6 hours in the continued presence of BoNT in or-
der to find the most effective concentration of BoNT/A for 
the inhibition of muscle contraction. Second, after induction 
of muscle contraction by high K+, 10 U of BoNT/A was add-
ed to determine whether BoNT/A directly inhibits muscular 
contractility. Third, EFS at 1, 4, 8, or 20 Hz, 100 V, 0.5-ms 
pulse width duration (square wave), and 60 s train duration 
was done (1 and 4 Hz for activation of the intrinsic nerves; 8 
and 20 Hz for the direct stimulation of muscle contraction). 
N-nitro-L-arginine methyl ester (L-NAME; 100 μM) was 
added to inhibit nitric oxide (NO)-mediated relaxation. After 
measuring initial control responses to EFS and ACh 100 μM, 
the same experiment was repeated with the addition of 
BoNT/A (10 U). Fourth, contractile responses to EFS were 
measured with antral muscle strips excised 24 and 48 hours 
after antral intramuscular injection of BoNT/A.
Histological examination
Antral muscle strips around the BoNT/A injection site were 
removed and immersed in 10% formalin for 6 hours. After 
fixation, tissues were embedded in paraffin, and 5 μm sec-
tions were stained with hematoxylin and eosin. Pathologic 
changes in the injected area were compared with those of 
controls under light microscopy.
rophy. Its clinical effect starts 24 to 72 hours after adminis-
tration of toxin and lasts for 2-6 months.2
Recently, SNAP-25, a substrate for BoNT/A, was found 
in the smooth muscle of feline esophagus5 and it inhibited 
potassium currents in functional studies of circular smooth 
muscle cells.6 This suggests a role for SNAP-25 in regulat-
ing muscle contractility and the possibility of a novel mech-
anism for BoNT. Actually, this novel mechanism was previ-
ously suggested in an in vitro study.7 A higher concentration 
of BoNT/A (10 U/mL) directly inhibited smooth muscle 
contractility, whereas at a lower concentration (2 U/mL) it 
inhibited acetylcholine (Ach) release from cholinergic 
nerves without affecting Ach-induced contractions. In that 
study, however, muscle strips were studied after 6 hours of 
exposure to high dose BoNT, instead of using a clinically 
important method, direct injection. Also, only short-term ef-
fects of BoNT were evaluated.
Therefore, the aims of our present study were 1) to deter-
mine whether other mechanisms for BoNT exist, especially 
direct inhibition of smooth muscle contractions and 2) to 
evaluate changes in the effects of BoNT on muscular con-
tractility over time.
MATERIALS AND METHODS
　　　
Antral muscle strip preparation
Guinea pigs, weighing 300-350 g, were used for the study. 
Guinea pigs were killed by anesthesia using intraperitoneal 
injection of pentobarbital sodium 35-40 mg/kg and decapi-
tation. The stomachs were removed, opened along the lon-
gitudinal axis, and rinsed with Krebs-Hanseleite buffer (in 
mM: 120 NaCl, 4.6 KCl, 2.5 CaCl2, 1.2 MgCl2, 22 NaH-
CO3, 1.2 NaH2PO4, and 11.5 glucose, oxygenated with 95% 
O2-5% CO2, pH 7.4). The mucosa was removed from the 
antrum. Antral circular muscle strips were prepared and 
suspended in 5 mL organ baths. Muscle tension was mea-
sured along the circular muscle direction using an isometric 
force transducer (BIOPAC TSD 105; BIOPAC system, 
Inc., Santa Barbara, CA, USA). Muscle strips were sus-
pended between platinum electrodes placed adjacent and 
parallel to the long axis of the muscle strip. Electrodes were 
connected to an electric stimulator (model S88K, Grass In-
struments, Quincy, MA, USA). After 2 hours of equilibra-
tion period, contractile force was measured. The experi-
mental procedures were conducted in accordance with the 
guidelines of the University of Yonsei Animal Care and 
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are presented as mean±SEM. The Mann-Whitney U test 
was used to compare 2 groups. One-way ANOVA was used 
for 3 or more groups. p<0.05 was considered to indicate a 
significant difference.
 
RESULTS
 
Effect of various concentrations of BoNT/A on 
muscular contractions to EFS
BoNT/A reduced EFS-induced contractions in a concentra-
tion-dependent fashion. In normal Krebs solution, EFS (4 
Hz, 60 s) induced contractions of muscle strips (0.64±0.18 
kg/cm2) (n=7). Addition of 2, 4, or 10 U of BoNT/A de-
creased EFS-induced contractile responses to 0.52±0.14, 
0.43±0.12 and 0.34±0.15 kg/cm2 (n=7, p<0.05), respective-
ly (Fig. 1). Ten U of BoNT/A was the most effective dose 
for the inhibition of muscle contraction.
Effect of BoNT/A on muscle contractions in response to 
high K+
BoNT/A had an inhibitory effect on muscular contractility 
induced by high K+. High K+ depolarizes the smooth mus-
cle cell membrane and opens voltage-dependent calcium 
channels, which results in an influx of extracellular calcium 
and an activation of contractile machinery.8,9 In this study, 
high K+ (60 mM) induced a considerable muscle contrac-
tion (2.65±0.75 kg/cm2) (n=4), and this contractile response 
was substantially reduced (-47%) by BoNT/A (10 U) to 
1.39±0.37 kg/cm2 (n=4, p<0.05) (Fig. 2).
Effect of L-NAME and BoNT/A on muscle contractions 
induced by EFS
BoNT/A decreased EFS-induced muscle contractions (1 
and 4 Hz for the activation of intrinsic nerves; 8 and 20 Hz 
for the direct stimulation of muscle contraction). The addi-
tion of L-NAME (100 μM) increased contractile responses 
to EFS (n=4, p>0.05). When both L-NAME (100 μM) and 
BoNT/A (10 U) were applied to the muscle strips, there 
was no significant change in EFS-induced muscle contrac-
tions (EFS at 1, 4, 8, or 20 Hz) (n=4, p>0.05) (Fig. 3).
Effect of L-NAME and BoNT/A on muscle contractions 
to Ach
BoNT/A caused a significant decrease in muscular contrac-
tions in response to ACh. The addition of L-NAME (100 
μM) increased contractile responses to Ach (100 μM) (n=4, 
Data analysis
Contractile responses were expressed as kg/cm2. All data 
Fig. 1. Effect of various concentrations of BoNT/A on muscular contrac-
tions to EFS. BoNT/A reduced the EFS-induced contraction in a concentra-
tion-dependent fashion. (A) Tension recordings from guinea pig antral mus-
cle strips showing progressive loss of contractile force with increasing 
concentration of BoNT/A. (B) Contractions of muscle strips to EFS were in-
hibited most effectively by 10U/m of BoNT/A. EFS, electric field stimulation.
Fig. 2. Effect of BoNT/A on muscle contractions to high K+. BoNT/A 10 U 
significantly inhibited contractile response induced by High K+ (60 mM).
Fig. 3. Effect of L-NAME and BoNT/A on muscle contractions induced by 
EFS. The addition of L-NAME (100 μM) increased contractile responses to 
EFS (p>0.05). When L-NAME (100 μM) and BoNT/A (10 U) were both ap-
plied to the muscle strips, there was a slight decrease of in EFS-induced 
muscle contractions (EFS at 1, 4, 8, or 20 Hz; p>0.05). L-NAME, N-nitro-L-
arginine methyl ester; EFS, electrical field stimulation.
Control
2 sec
0.2 g
4 U2 U 10 U
0.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Te
ns
io
n 
(k
g/
cm
2 )
Te
ns
io
n 
(k
g/
cm
2 )
Control
High K+
n=4
BoNT/A+ high K+
BoNT 2 U BoNT 4 U BoNT 10 U
p<0.05
p<0.05
0.4
0.6
0.8
1.0
1.2
1.4
Te
ns
io
n 
(k
g/
cm
2 )
1 Hz 4 Hz 8 Hz 20 Hz
p>0.05
 Control (n=4)
 L-NAME (n=4)
 L-NAME+BoNT/A (n=4)
A
B
A Inhibitory Effect of Botulinum Toxin A 
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 2012 971
significantly decreased (at 1, 4, 8, or 20 Hz, respectively; 
n=4, p<0.05). However, no significant difference existed 
between contractile responses to EFS in the presence of 
BoNT/A (4 or 10 U; n=4, p>0.05) (Fig. 5).
Pathologic changes in antral muscle strips taken 24 and 
48 hours after antral intramuscular injection of BoNT/A
There were no pathologic changes in the muscular strips 
taken 24 and 48 hours after the injection of BoNT/A 4 U. 
However, in case of injection with BoNT/A 10 U, intra-
muscular hemorrhage and infiltration of inflammatory cells 
were detected (Fig. 6).
DISCUSSION
In this study, we tried to acquire evidence of direct inhibi-
tion of muscular contraction by BoNT. At BoNT/A concen-
trations of 4 & 10 U, contractile responses of smooth mus-
cle strips to low (1 & 4 Hz) and high (8 & 20 Hz) frequency 
EFS were significantly inhibited, and these effects lasted 
for at least 48 hours. Also, BoNT/A inhibited muscular con-
tractions caused by high K+ and ACh. Considering that high 
K+ depolarizes the smooth muscle cell membrane and acti-
vates muscle contractions, these results suggest a possibility 
of a novel mechanism for BoNT/A-direct inhibition of 
muscle contraction.
NO is involved in both short-lasting and sustained non 
adrenergic non cholinergic relaxation.10 In the present 
study, pretreatment with L-NAME inhibited NO-mediated 
relaxation and considerably increased contractile response 
p>0.05). However, when both L-NAME (100 μM) and 
BoNT/A (10 U) were applied to muscular strips, there was 
a significant decrease in muscle contraction in response to 
ACh (n=4, p<0.05) (Fig. 4).
Contractile responses to EFS of antral muscle strips 
excised 24 and 48 hours after injection of BoNT/A
At 24 hours after antral intramuscular injection of BoNT/A 
(4 & 10 U), there was a significant decrease in muscular 
contraction in response to EFS (1, 4, 8, or 20 Hz, respec-
tively; n=4, p<0.05). However, no significant difference 
was found between EFS-induced contractile responses in 
the presence of BoNT/A (4 and 10 U; n=4, p>0.05).
At 48 hours after the injection of BoNT/A, overall con-
tractile responses to EFS were slightly enhanced compared 
to 24 hours. Muscular contractions in response to EFS were 
Fig. 4. Effect of L-NAME and BoNT/A on muscular contractions to ACh. The 
addition of L-NAME (100 μM) increased (p>0.05) contractile responses to 
Ach (100 μM). However, when L-NAME (100 μM) and BoNT/A (10 U) were 
both applied to muscular strips, there was a significant decrease in muscle 
contraction in response to ACh (p<0.05). L-NAME, N-nitro-L-arginine meth-
yl ester; ACh, acetylcholine.
Fig. 5. Contractile responses to EFS of antral muscle strips excised 24 and 48 hours after injection of BoNT/A. (A) At 24 hours after intragastric injection of 
BoNT/A (4 & 10 U), there was a significant decrease in muscular contraction in response to EFS (1, 4, 8, or 20 Hz; p<0.05). However, no significant difference 
was found between EFS-induced contractile responses in the presence of BoNT/A (4 and 10 U; p>0.05). (B) At 48 hours after injection of BoNT/A, overall 
contractile responses to EFS were slightly enhanced compared to 24 hours. Muscular contractions in response to EFS were significantly decreased 
(p<0.05). No significant difference existed between contractile responses to EFS in the presence of BoNT/A (4 or 10 U; p>0.05). EFS, electric field stimulation.
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gurgitation, and chest pain), decrease lower esophageal 
sphincter pressure, and improve esophageal emptying, 
compared with the injection of placebo.16,17 BoNT injection 
into the internal or external anal sphincter causes relaxation 
of the anal sphincters, enhances microcirculation at the fis-
sure site, and promotes fissure healing.18,19 Most of these 
studies evaluated results by symptom control and improve-
ments in manometric findings, whereas few studies have 
directly investigated changes in muscle tone and mechanism 
of action over time. Typically, a 24 to 72 hour delay exists 
between the administration of toxin and the onset of clinical 
effects.2 Even though the delay in onset of clinical effects is 
not fully understood, the delay could be related to either a 
delayed or protracted effect of the protease on substrate me-
tabolism, or to proximal spread of the toxin to the central 
nervous system.20 However, in this study, the onset of ef-
fects occurred at least 24 hours after the injection of BoNT/
A. Furthermore, it took BoNT/A only 2 hours to induce re-
laxation of muscle strips. Therefore, BoNT/A might have a 
different mechanism of action to relieve symptoms caused 
by various diseases, instead of simple relaxation of muscle. 
Also, the onset of BoNT/A effects might depend on the 
amount of BoNT/A: a relatively large amount of BoNT/A 
could have a fast direct effect on muscle and nerve, while 
small amounts might take a longer time for diffusion and 
can not induce direct inhibition of muscular contractility. 
Interestingly, muscle strips taken 24 & 48 hour after the 
injection of BoNT/A were not responsive to high frequency 
EFS. These results indicate that BoNT/A directly inhibits 
muscular contractility, and it is possible that other factors 
affected muscle tone after surgery. For example, post opera-
tive ileus of the stomach could be responsible for decreased 
contractile responses to EFS. However, given that controls 
also underwent post operative ileus after surgery, the con-
to EFS and ACh. Furthermore, addition of BoNT/A and L-
NAME notably decreased muscle contractions in response 
to ACh. In contrast, the inhibition of contractile responses 
to EFS when induced by BoNT/A and L-NAME was not 
significant. It is, therefore, possible that muscle strips might 
be in poor condition after 2 hours’ incubation, or muscle 
contraction to low & high frequency EFS may not be strong 
enough to show a profound BoNT/A-induced decrease in 
muscle tone when compared with the contractile response to 
ACh and High K+. 
The classical mechanism for BoNT is to inhibit ACh re-
lease from cholinergic nerves. Recently, several studies have 
suggested the possibility of other mechanisms of action of 
BoNT. In addition to be a local muscle relaxant, BoNT ap-
pears to act at the level of central nervous system.11,12 BoNT 
can also alleviate pain by interacting with several other neu-
ronal signaling pathways such as those triggered by sub-
stance P, glutamate, and calcitonin gene related peptide.13,14 
BoNT/A selectively degrades SNAP-25, a protein required 
for vesicle fusion, thereby preventing neurosecretory vesi-
cles from fusing with the nerve membrane.15 Interestingly, 
SNAP-25 also exists in esophageal smooth muscle and in-
hibits outward potassium currents. Therefore, if SNAP-25 is 
cleaved by BoNT/A, esophageal smooth muscle tone would 
be decreased by hyperpolarization of the membrane.6 This 
might be the mechanism for direct inhibition of muscle 
contraction by BoNT/A. However, whether SNAP-25 ex-
ists in stomach smooth muscle cell of guinea pig, or wheth-
er BoNT/A can enter smooth muscle cells is not yet certain. 
These points need to be verified in future studies. 
Nowadays, BoNT/A is used therapeutically for a variety 
of spastic disorders of gastrointestinal smooth muscle. Injec-
tion of BoNT into the lower esophageal sphincter has been 
shown to reduce the symptoms of achalasia (dysphasia, re-
Fig. 6. Pathologic changes in antral muscle strips taken 24 and 48 hours after intragastric injection of 10 U BoNT/A. Intramuscular hemorrhage and infiltra-
tion of inflammatory cells were detected in the muscle strips taken 24 (A) and 48 (B) hours after injection of BoNT/A (H&E stain, A: ×400, B: ×100).
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siderably decreased contractile response to high frequency 
EFS may be caused by BoNT/A. In addition, inflammatory 
responses including physical damage could have an influ-
ence on the contractility of antral muscle strips. Actually in 
the present study, hemorrhage and inflammatory responses 
were noted in the muscle strips taken 24 & 48 hours after 
antral intramuscular injection of 10 U of BoNT/A. Even 
though muscle strips receiving 4 U of BoNT/A did not have 
any sign of inflammation or hemorrhage, contractile re-
sponses of these strips to EFS were very similar to the re-
sponses of muscle strips receiving 10 U of BoNT/A. There-
fore, inflammation or physical damage itself does not seem 
to be the cause of decreased contractile responses to EFS.
In the beginning of this study, we planned to evaluate 
muscle tone one week after the injection of BoNT/A. How-
ever, once guinea pigs underwent surgery and injection, they 
could not eat enough food and most of them died within 
one week. Similar outcomes were observed with a lower 
concentration of BoNT/A. Because 4 U of BoNT/A did not 
cause any inflammation or hemorrhage around the injection 
site, physical or chemical damage might not be the direct 
cause of the deaths of the guinea pigs. One possible explana-
tion is the inhibition of antral motility by BoNT/A: BoNT/A 
injected into the gastric wall of rats could reduce body 
weight and food intake through the inhibition of antral mo-
tility.21 The other explanation involves systemic toxicity of 
BoNT. The exact lethal dose for the injection of BoNT is 
not yet known. In the case of intramuscular injection in 
monkeys, the fatal dose range of BoNT/A was 38-42 U/
kg.22 Considering the body weight of a guinea pig, 10 U of 
BoNT/A could be enough to cause death.
In summary, BoNT/A can directly inhibit antral muscular 
contractility, in addition to blocking the release of ACh from 
nerves, and this effect lasts at least 48 hours after antral in-
tramuscular injection of BoNT/A. These results provide an 
evidence for a new mechanism of BoNT-direct inhibition 
of muscular contraction.
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